ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeNoninfectious uveitic macular edema (UME) is a major cause of visual impairment and remains challenging in refractory cases. Although adalimumab (ADA) is an effective biologic therapy, its delayed onset may limit early disease control, suggesting a potential role for bridging strategies such as local corticosteroid injection. This study compared ADA monotherapy with ADA combined with sub-Tenon's triamcinolone acetonide (STTA) bridging therapy in refractory noninfectious UME.
methodsIn this retrospective longitudinal cohort study, 30 patients (44 eyes) with refractory noninfectious UME treated with ADA (2015-2025) were included. Patients received either ADA monotherapy or ADA with STTA bridging therapy. Outcomes included time to improvement (≥ 20% reduction in central subfield thickness (CST) with reduced cystoid spaces), relapse after resolution, longitudinal CST changes, best-corrected visual acuity (BCVA, LogMAR), and intraocular pressure (IOP). Time-to-event analyses were performed using Cox regression, and Longitudinal data using generalized estimating equation models adjusted for baseline covariates.
resultsBridging therapy was associated with a shorter time to improvement (log-rank p = 0.008; HR 2.850, 95% CI 1.402-5.794; p = 0.004). Adjusted analyses showed greater visual improvement in the bridging group at 12 months (difference 0.307 LogMAR; p < 0.001) and at 15, 24, and 36 months (p < 0.05). Greater CST reductions were observed at 3, 18, 21, and 36 months (p < 0.05). Relapse risk did not differ significantly (HR 0.711, 95% CI 0.155-3.272; p = 0.662). IOP changes were generally comparable.
conclusionADA combined with STTA bridging therapy was associated with earlier anatomical improvement and additional visual benefits compared with ADA monotherapy, without increased relapse risk.
Indexed as
Identifiers
42467200What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.